The role of humoral autoimmunity in the aetiology of achalasia.

Completed

• Conditions: Achalasia; Oesophageal motility disorder; 10017977; 10003816; 10029317

• Registration Number: NL-OMON37385
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

Patients with achalasia:
- Diagnosis of achalasia confirmed by:
- Oesophageal manometry; aperistalsis, LOS dysrelaxation and hypertensive LOS (>10mmHg).
- Barium oesophagogram; delayed emptying, aperistalsis and dilatation of the oesophagus with narrowing of the distal oesophagus.
- Eckhardt score * 2.
- Age 18-75 years.
- Written informed consent;Healthy controls:
- Age 18-75 years.
- Written informed consent

Exclusion Criteria

Patients with achalasia:
- Pseudoachalasia
- Chagas disease
- Upper gastrointestinal malignancy;Healthy controls:
- Symptoms suggestive of oesophageal disease.
- History of malignancy.
- History of diseases affecting the upper gastrointestinal tract (gastro-oesophageal reflux disease, eosinophilic oesophagitis)
- Pseudoachalasia
- Chagas disease
- Autoimmune diseases

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Difference in the presence of antimyenteric neuronal antibodies in patients<br /><br>with achalasia and controls.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Identify the targeted antigen(s) of the antimyenteric neuronal antibodies.<br /><br>- General quality of life<br /><br>- Quality of life related to achalasia<br /><br>- Eckhardt clinical symptom score</p><br>